

Title page

Histone deacetylase inhibitors exert time-dependent effects on Nuclear Factor-kappa B but consistently suppress the expression of labour-associated, pro-inflammatory genes in human myometrial cells.

Tamsin M Lindström*, Aarthi R Mohan, Mark R Johnson, and Phillip R Bennett

Department of Reproductive Biology, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK; TML, ARM, PRB

Department of Maternal and Fetal Medicine, Chelsea and Westminster Hospital, Imperial College London, London SW10 9NH, UK; MRJ

Running title: HDACi effects in human myometrial cells

*To whom correspondence should be addressed: Tamsin M Lindstrom, 3rd Floor IRDB,
Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN,
UK; Fax: 0030 210 9654491; Phone: +1 415 994 6230;

Email: tamsinlindstrom@gmail.com

Number of text pages: 43
Number of tables: 1
Number of figures: 8
Number of references: 45
Abstract: 250 words
Introduction: 731 words
Discussion: 1, 476 words

Abbreviations: TSA, trichostatin A; SAHA, suberoylanilide hydroxamic acid; HATs, histone acetyltransferases; HDACi, histone deacetylase inhibitors; IL, interleukin; RANTES, regulated-upon-activation normal-T-cell-expressed and –secreted; NF- κ B, nuclear factor-kappa B; CRM1, chromosome maintenance 1; COX-2, cyclo-oxygenase-2; I κ B, inhibitor of kappa B; IKK, inhibitor of kappa B kinase; EMSA, electromobility shift assay; HH, histone H; ac, acetylated; SIRT1, Sirtuin 1; NLS, nuclear localisation signal; NES, nuclear export signal; SCF ^{β -TrCP}; ligase composed of Skp1, Cdc53/Cu11, and a specificity-conferring F-box protein, in this case beta-transducin repeat-containing protein (β TrCP); PBS, phosphate buffered saline; DMSO, dimethyl sulfoxide.

Abstract

Premature activation of the inflammatory processes that mediate human parturition leads to preterm birth, a major clinical problem associated with neonatal morbidity and mortality. Histone deacetylase inhibitors (HDACi) are currently in clinical trials for the treatment of inflammatory disorders. Recent evidence suggests that there may be a therapeutic use for HDACi in the management of preterm birth, with administration of HDACi to pregnant mice shown to delay delivery. Since NF- κ B is a key orchestrator of the inflammatory response and plays a pivotal role in parturition, it is important to understand how administration of HDACi might affect NF- κ B activity in human uterine tissues. We show here that the effects of HDACi on NF- κ B in human myometrial cells are time-dependent. Short-term exposure to HDACi enhanced IL-1 β -induced NF- κ B activity as a result of potentiating IKK β activity, thereby leading to persistent turnover of I κ B α/ϵ proteins and prolonging NF- κ B phosphorylation, nuclear localisation and DNA binding. Conversely, long-term HDACi treatments resulted in repression of NF- κ B DNA binding. Nevertheless, both short- and long-term HDACi treatments inhibited the expression of four labour-associated pro-inflammatory genes (*COX-2*, *IL-8*, *IL-6*, *RANTES*), and this was associated with repression of pro-inflammatory transcription factor c-Jun. Taken together, our data indicate that HDACi exert anti-inflammatory effects in human myometrium and may thus be useful in achieving a myometrial gene expression profile that favours uterine quiescence. However, co-administration of an IKK β inhibitor may be both necessary and sufficient to circumvent potential induction of labour-associated pathways that could result from HDACi-induced augmentation of NF- κ B activity.

Introduction

During parturition, myometrium undergoes a transition from a state of quiescence to one of contractility, resulting in delivery of the neonate. Although the molecular mechanisms that underpin this transition are poorly understood, it is widely accepted that parturition is an inflammatory process, involving the up-regulation of multiple pro-inflammatory genes (Romero et al., 2006). Premature activation of uterine pro-inflammatory pathways can lead to preterm birth, a major clinical problem that occurs in 5-10% of pregnancies and is associated with 70-75% of neonatal morbidity/mortality (Wen et al., 2004).

Histone acetylation plays a major role in gene transcription, enabling the partial unravelling of local chromatin structure that is required to make the DNA accessible for binding by transcription factors and the basal transcription machinery (Li et al., 2004). Acetylation is reversible and reflects a dynamic balance between the activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Aberrant recruitment of HDACs to promoters and/or overexpression of HDACs are observed in cancer cells, and pharmacological HDAC inhibitors (HDACi) are in clinical trials for the treatment of cancers (Bolden et al., 2006). Cancer is an inflammatory disease, and HDACi are beginning to be considered as therapeutic agents in other inflammatory disorders (Luhrs et al., 2002). Recent studies suggest that there could also be a clinical use for HDACi in the prevention of preterm delivery (Condon et al., 2003; Phillips et al., 2005). Notably, human parturition is characterised by a decrease in myometrial levels of HATs, global histone H3 (HH3) acetylation decreases in both human and murine uterine tissue at term,

and administration of HDACi to pregnant mice late in gestation delays delivery (Condon et al., 2003).

Since histone hyperacetylation is associated with transcriptional activation (Li et al., 2004), the inhibition of HDAC activities might be expected to result in a global increase in gene expression. However, microarray studies indicate that HDACi are selective in their effects on gene expression, altering the expression of only 2-10% of genes analysed and down-regulating as many genes as they up-regulate (Kelly and Marks, 2005). The paradoxical inhibitory effects of HDACi on gene expression implies that other components of the transcriptional response, in addition to histones, are regulated by acetylation. Indeed, an increasing number of diverse nonhistone proteins are being identified as targets for HATs and HDACs. Nuclear factor-kappa B (NF- κ B) is one nonhistone protein that both recruits HATs and HDACs to target gene promoters and is itself a substrate for HATs/HDACs (Quivy and Van Lint, 2004). The class I HDACs 1, 2, and 3, and the class III HDAC Sirtuin 1 (SIRT1) have been implicated in the inhibition of NF- κ B-mediated transcription, with HDAC3 and SIRT1 reportedly acting to deacetylate NF- κ B itself (Chen et al., 2001; Quivy and Van Lint, 2004; Yeung et al., 2004).

NF- κ B is key to the orchestration of the inflammatory response, serving to induce the expression of numerous pro-inflammatory genes (Lindstrom and Bennett, 2005b), and the anti-inflammatory effects of HDACi in patients with ulcerative colitis are associated with diminished NF- κ B activation (Luhrs et al., 2002). NF- κ B is a transcription factor family comprising five members, p65, p50, p52, c-rel and RelB, which form heterogeneous dimers. In resting cells, NF- κ B is retained in the cytoplasm in an inactive form through association with the I κ B proteins, namely

I κ B α , I κ B β and I κ B ϵ . In the classic pathway, pro-inflammatory signalling converges on the I κ B kinase (IKK) complex. Once activated, the IKK β subunit phosphorylates I κ B α on serines 32/36 (Traenckner et al., 1995), and this phosphorylation targets I κ B α for ubiquitination by the SCF ^{β} -TrCP ubiquitin ligase. Ubiquitinated I κ B α is subsequently degraded by the 26S proteasome, thereby releasing p50/p65 NF- κ B dimers from the cytoplasmic I κ B α /NF- κ B complex, and allowing them to translocate to the nucleus where they bind to target gene promoters to modulate transcription.

Acetylation/deacetylation can affect NF- κ B-mediated transcription on multiple levels. Reports on the effects of HDACi on NF- κ B activity are conflicting (Chen et al., 2001; Takada et al., 2006). Similarly, the effects of HDACi on pro-inflammatory gene expression vary in a promoter-, stimulus-, and cell type-specific manner (Horion et al., 2007). Unsurprisingly given its importance in inflammation, accumulating evidence suggests that NF- κ B plays a pivotal role in parturition (Lindstrom and Bennett, 2005b; Mendelson and Condon, 2005). In the present study, we investigate the effects of HDACi on NF- κ B activity and pro-inflammatory gene expression in primary human myometrial cells to assess the therapeutic potential of HDACi in the maintenance of myometrial quiescence.

Materials and Methods

Reagents

Antibodies against p65, p50, I κ B α , I κ B ϵ , COX-2, c-Jun, and the IKK β antibody used for Western immunoblotting were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against serine 32/36-phosphorylated I κ B α , against serine 536-phosphorylated p65, as well as the IKK β antibody used for immunoprecipitation, were from Cell Signaling Technology (Danvers, MA, USA). The anti-acetylated histone H4 antibody was from Upstate Cell Signaling Solutions (Billerica, MA, USA), and the antibody against lamin B was from Calbiochem (Nottingham, UK). Trichostatin A (TSA) and the α -smooth muscle actin antibody were from Sigma-Aldrich (Exeter, UK). Recombinant human IL-1 β was from R&D Systems (Abingdon, UK), and suberoylanilide hydroxamic acid (SAHA) was from BioVision (Mountain View, CA, USA). Sc-514 was purchased from Calbiochem. TSA, SAHA and sc-514 were dissolved in dimethyl sulfoxide (DMSO). All experiments were vehicle-controlled and DMSO, at the concentrations used in this study, did not affect any aspect of the NF- κ B signaling pathway.

Primary human myometrial cell culture

Institutional Ethics Committee approval was obtained for the collection of myometrial tissues from healthy women at 37-39 weeks gestation, and all patients gave informed consent. Myometrial biopsies were collected at term from the upper margin of uterine incision at the time of lower segment caesarean section, as indicated by breech presentation or previous caesarean section. Myometrial tissue was dissected, rinsed in phosphate-buffered saline (PBS), and digested in PBS containing 15 mg/ml collagenase 1A (Sigma-Aldrich), 15 mg/ml collagenase X

(Sigma-Aldrich), and 50 mg/ml bovine serum albumin (Sigma-Aldrich) for 45 min at 37° C. The cell suspension was filtered through a cell strainer, and pelleted at 400 g for 5 min. Cells were used between passage numbers 1-5. Cells were grown to 80% confluence in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) (Sigma-Aldrich), 2 mM L-GLUTAMINE (Gibco, Paisley, UK), 100 U penicillin-streptomycin (PS) (Gibco), then incubated overnight in DMEM containing 2% FCS, 2 mM L-glutamine, 100 U (PS) and the effects of TSA or SAHA on unstimulated or IL-1 β -stimulated cells examined.

Western immunoblotting

Nuclear and cytoplasmic extracts were prepared as previously described (Lindstrom and Bennett, 2005a). For whole-cell lysates, cells were lysed for 20 min on ice in radioimmunoprecipitation assay buffer (1% NP-40, 1% Triton X 100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM Tris pH 8.0, 2 mM NaF). Protein concentrations of cell lysates were determined using Bio-Rad DC protein assay reagents (Bio-Rad Laboratories, Hertfordshire, UK). Western blotting was performed as previously described (Lindstrom and Bennett, 2005a). The levels of cellular α -smooth muscle actin were used as a loading control, and membranes were re-probed with antibodies against lamin B to confirm the integrity of cell fractionation.

Electrophoretic Mobility Shift Assay

Nuclear lysates were prepared and electrophoretic mobility shift assays (EMSAs) performed as previously described (Lindstrom and Bennett, 2005a). Consensus double-stranded oligonucleotides were obtained from Promega Life Science (Southampton, UK), NF- κ B: 5'-AGT TGA GGG GAC TTT CCC AGG C-3' (specific binding site sequences underlined).

Transient transfections

Cells at ~70% confluence in 24-well plates were transfected using the liposome reagent Fugene-6 (Roche, Welwyn Garden City, UK) according to the manufacturer's instructions. Cells were transfected with 0.4 µg/well of an NF-κB-dependent firefly luciferase reporter construct (NF-κB-LUC) at a 3:1 ratio of Fugene-6 to DNA, in DMEM, 10% FCS, together with 0.04 µg/well CMV-Renilla as an internal control for transfection efficiencies. NF-κB-LUC contains two tandem repeats of the sequence 5'-GGG GAC TTT C CC TGG GGA CTT TCC CTG GGG ACT TTC CC-3', which contains three copies of the decameric κB site (underlined) upstream of a minimal beta-globin promoter driving a luciferase gene (in a pGL3 vector). NF-κBmut-LUC, in which the κB sites are mutated, was used as a control to confirm NF-κB-mediated transactivation. The medium was replaced with DMEM containing 2% FCS 16 h after transfection, and the cells incubated for a further 24 h prior to treatment with TSA, SAHA and/or IL-1β. Reporter activity was analysed in a firefly luciferase assay (Promega Life Sciences) and firefly values were normalised according to the internal control renilla luciferase values. The renilla luciferase assay was carried out by adding coelenterazine substrate (Calbiochem) in 0.5 M HEPES pH 7.8, 40 mM EDTA to the firefly luciferase reaction.

***In vitro* IKK kinase assay**

Following treatment, cells were washed 2x in PBS, scraped into 10 ml PBS and centrifuged at 400 x g for 5 min. The PBS was removed and the cell pellet resuspended in 400µl nondenaturing cell lysis buffer (New England Biolabs, Hitchin, Hertfordshire, UK). Cell lysates were incubated on ice for 20 min, and centrifuged for 20 min at 13 000 rpm at 4°C. The supernatants were

MOL #42838

transferred to a fresh eppendorf, and endogenous IKK β was immunoprecipitated from 400-500 μ g protein lysate using a rabbit anti-IKK β antibody (L570, Cell Signaling) at a 1/100 dilution. The cell lysate/antibody mix was incubated at 4°C on a rotator overnight. 20 μ l of protein sepharose A beads (Amersham Biosciences, Buckinghamshire, UK) were added to the cell lysate/antibody mix and replaced on the rotator for a further 2 h. The beads were then centrifuged at 13 000 rpm at 4°C for 30 sec, the supernatant discarded, and the beads washed 2x in lysis buffer and 2x in kinase buffer (New England Biolabs). 50 μ l of kinase buffer supplemented with 100 μ M ATP (New England Biolabs) and 2 μ g of GST-I κ B α fusion protein (Europa Bioproducts Ltd, Cambridge, UK) was added to the beads. The kinase reaction was vortexed and incubated in a 30°C shaking waterbath for 30 min. 10 μ l of 3x Laemmli sample buffer were added to stop the reaction and the samples were boiled for 5 min at 100°C. Samples were centrifuged at 13 000 rpm for 30 sec and the supernatants resolved on a 10% SDS-PAGE gel. Whole-cell lysate was loaded in parallel as a positive control and samples immunoprecipitated with preimmune rabbit IgG were included as a negative control. Western immunoblot analysis was next performed using antibodies against I κ B α phosphorylated on serines 32/36 to assess kinase activity. To confirm equal immunoprecipitation of the kinase, membranes were also probed with an antibody against IKK β (Santa Cruz Biotechnology). Membranes were then stripped and re-probed for total I κ B α (Santa Cruz Biotechnology), to confirm the presence of equal amounts of substrate.

Quantitative real-time RT-PCR

Total RNA was extracted using RNA STAT-60 reagent (AMS Biotechnology, Abingdon, Oxon, UK) according to the manufacturer's specifications. To remove any contaminating DNA, 1 μ g of

MOL #42838

total RNA was digested with 0.5 µl DNaseI in 1X DNaseI reaction buffer (Invitrogen, Paisley, UK) in a total volume of 5 µl at room temperature for 15 min. The reaction was terminated by the addition of 0.5 µl 25 mM EDTA and incubation at 65 °C for 15 min. The whole of this reaction was subsequently used for first strand cDNA synthesis with Superscript™ First Strand Synthesis System for RT-PCR (Invitrogen Life Technologies), according to the manufacturer's instructions. For quantitative real-time RT-PCR, the resulting cDNA was analysed in triplicate using SYBR Green Master Mix (Applied Biosystems, Warrington, Cheshire, UK) in the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). The values obtained were normalised according to transcript levels of the ribosomal protein *L19*, whose expression has been used as a control to normalise gene expression in many contexts, including in human endometrium in a study of recurrent pregnancy loss (Francis et al., 2006), and in a pro-inflammatory setting (Wan et al., 2007). The primers used to analyse the different transcripts were designed with the software Primer Express™ (Applied Biosystems): *IKBA* FW 5'-CCTGGCCCAAACGTCTTATT-3' and RV 5'-TGATCTTTCTCGTCCCCT ACAA-3'; *COX-2* FW 5'-GCTCAAACATGATGTTTGCATTC-3' and RV 5'-GCTGGCCCTCGCTTATGA-3'; *IL-8* FW 5'-AAGGAACCATCTCACTGTGTGTAAAC-3' and RV 5'-ATCAGGAAGGCTGCCAAGAG-3'; *IL-6* FW 5'-CACCGGGAACGAAAGAGAAG-3' and RV 5'-AGGCGCTTGTGGAGAAGGA-3'; *RANTES* FW 5'-GCATCTGCCTCCCATATTC-3' and RV 5'-AGTGGGCGGGCAATGTAG-3'; and *L19* FW 5'-GCGGAAGGGTACAGCCAAT-3' and RV 5'-GCAGCCGGCGCAA-3'.

Results

HDACi exert time-dependent effects on NF- κ B activation

Data on the effect of pharmacological HDAC inhibition on NF- κ B appear contradictory, with some studies showing a potentiation (Adam et al., 2003; Chen et al., 2001; Yeung et al., 2004) and others reporting an inhibition (Luhrs et al., 2002; Takada et al., 2006) of NF- κ B activity. A number of studies using the same HDACi compound employed very different treatment protocols, with exposure of cells to HDACi ranging from 1-24 h. IL-1 β activates NF- κ B, is considered a master regulator of inflammation in diverse disease processes, its expression increases in the uterus as term approaches and in association with labour onset (Elliott et al., 2001; Mendelson and Condon, 2005), and administration of IL-1 β can induce labour in the rhesus monkey (Vadillo-Ortega et al., 2002). We therefore tested both long- and short-term effects of the HDACi TSA on IL-1 β -induced NF- κ B activity in human myometrial cells.

Cells were pre-incubated with 50 nM, 100 nM or 500 nM of TSA for 1 h to establish inhibition of HDAC activity, and then stimulated with IL-1 β , in order to activate NF- κ B, for 2 h or 24 h. Treatment of cells with TSA did not lead to any overt morphological changes at any time points, nor did it induce the activation of caspase-3 or poly(ADP-ribose) polymerase (data not shown), in agreement with previous studies showing that HDACi induce apoptosis in cancer cells but not in normal cells (Kelly and Marks, 2005). Nuclear extracts were prepared and binding of proteins to a consensus κ B probe was assessed by EMSA (Fig. 1A&B). TSA alone had no effect on NF- κ B DNA binding at any time point. However, TSA enhanced IL-1 β -stimulated NF- κ B DNA binding at 2 h (*lanes 3-6*), while, conversely, repressing IL-1 β -induced NF- κ B DNA binding at

24 h (*lanes 12-15*). Nuclear extracts used in the EMSA experiments were subjected to Western immunoblot analysis using an antibody that specifically recognises acetylated histone H4 (ac-HH4) to confirm the efficacy of TSA. IL-1 β alone had no effect on HH4 acetylation (Fig. 1D). Although TSA alone had no effect on NF- κ B DNA binding (Fig. 1A), TSA treatment resulted in the appearance of ac-HH4 by 2 h, presumably as a consequence of preventing HH4 deacetylation (Fig. 1D). However, ac-HH4 could not be detected at 24 h. To exclude non-specific effects of the TSA compound, suberoylanilide hydroxamic acid (SAHA), a structurally similar HDACi that also inhibits class I and II HDACs and is currently in clinical trials for cancer treatment (Kelly and Marks, 2005), was also used. Following a 1 h pre-incubation period, 5 μ M SAHA enhanced IL-1 β -stimulated NF- κ B DNA binding at 2 h, but repressed IL-1 β -stimulated DNA binding at 24 h (Fig. 1C), confirming the results obtained with TSA. Inhibition of NF- κ B DNA binding was already detectable by 6 h of incubation in the presence of TSA and IL-1 β (Fig. 1E&F).

To determine whether the effects of HDACi on NF- κ B DNA binding translated to an effect on NF- κ B transcriptional activity, myometrial cells were transiently transfected with an NF- κ B-dependent luciferase reporter. When cells were pre-incubated with TSA for 1 h, TSA alone had no effect on reporter activity, but resulted in a modest increase in IL-1 β -induced reporter activity (Fig. 1G), consistent with the effects of HDACi on NF- κ B DNA binding. Surprisingly, when cells were pre-incubated with TSA for 1 h and then stimulated with IL-1 β for 24 h, TSA did not diminish NF- κ B transcriptional activity, but rather exhibited a modest augmentation of IL-1 β -induced reporter activity (Fig. 1G). At this time, TSA alone was able to increase activity of the NF- κ B reporter. Mutation of the κ B sites abolished basal reporter activity, as well as the effects of IL-1 β and/or TSA, confirming that the luciferase readout was NF- κ B-specific under all

treatment conditions (Fig. 1G). The transfection data from the long-term incubation experiments are in contrast to the observations on NF- κ B DNA binding at these time points. A possible explanation is that TSA is exerting a positive effect on the transcriptional activity of NF- κ B independently of its DNA binding activity (see discussion).

Thus, caution must be exercised when interpreting and comparing results based on experiments using different lengths of exposure to HDACi. Short-term effects of HDACi most likely reflect direct effects of prolongation of acetylation on the NF- κ B pathway, whereas long-term treatments with HDACi reveal secondary, indirect effects on NF- κ B. Since enhancement of NF- κ B activity would be undesirable in the management of preterm labour, it was important to next elucidate the mechanisms by which HDACi potentiate NF- κ B activation during short-term treatments.

HDACi prolong IL-1 β -induced nuclear localisation and DNA binding of NF- κ B

In initial experiments aimed at characterising the primary, potentiating effects of HDACi on NF- κ B activity, myometrial cells were pre-incubated with TSA for 1 h and then stimulated with IL-1 β for 15 min, 2 h, and 4 h, and nuclear lysates prepared for analysis of NF- κ B DNA binding. TSA alone had no effect on NF- κ B DNA binding at any time, but TSA treatment enhanced IL-1 β -induced NF- κ B DNA binding at 15 min and 2 h post stimulation, but not at 4 h (Fig. 2A&B). Western immunoblot analysis demonstrated that TSA increased nuclear levels of p65 in a dose-dependent manner following IL-1 β stimulation, but not in the absence of IL-1 β (Fig. 2C). This was not due to a TSA-induced increase in p65 expression since cytosolic levels of p65 remained unchanged by TSA treatment. Although IL-1 β stimulation resulted in a readily detectable

MOL #42838

increase in nuclear p65 protein levels, a concomitant decrease in cytosolic p65 levels was not detected. This is commonly observed in a number of cell types and is a function of the proportionally high levels of cytosolic p65, such that the loss of a small fraction of total cytosolic p65 is not readily detectable (Mattioli et al., 2004). Similarly, treatment of cells with SAHA plus IL-1 β also resulted in increased p65 nuclear levels compared to IL-1 β treatment alone (data not shown).

A chase experiment was next performed to determine whether the potentiating effect of TSA on IL-1 β -induced NF- κ B requires the continuous presence of IL-1 β . Myometrial cells were incubated in the presence or absence of TSA for 1 h, and then stimulated with IL-1 β for 15 min. IL-1 β was subsequently withdrawn from the cells, and incubation continued for the indicated times in medium alone or in medium containing TSA alone. While TSA alone had no effect on NF- κ B, cells incubated with TSA exhibited more sustained NF- κ B DNA binding following the transient stimulation with IL-1 β , compared to cells incubated in medium alone (Fig. 2D, *compare lanes 3-5 with lanes 6-8*). This was associated with prolonged IL-1 β -induced nuclear expression of p65 and p50 proteins in TSA-treated cells.

Taken together, these findings suggest that the augmenting effect of TSA on IL-1 β -induced NF- κ B DNA binding occurs as a result of IL-1 β inducing the activation, and possibly acetylation, of components of the NF- κ B pathway, and TSA blocking the deacetylation of such components, thus delaying the post-induction down-regulation of the NF- κ B response.

HDACi suppress IκB protein reappearance

NF-κB activation is governed by an autoregulatory “post-induction repression” mechanism. Due to the presence of κB sites in the promoter of the *IKBA* gene, activation of NF-κB leads to the rapid resynthesis of IκBα, which accumulates in the nucleus and dissociates NF-κB from DNA-bound complexes. These newly formed IκBα/NF-κB complexes are then exported out to the cytoplasm, a process dependent on a nuclear export signal (NES) present in IκBα (Huang and Miyamoto, 2001). We have found that the levels of resynthesized IκBα following stimulation influence the duration of NF-κB activation in myometrial cells (unpublished data). It therefore seemed possible that modulation of IκBα by HDACi underlies the prolonged nuclear localisation and DNA binding of NF-κB in response to these compounds. The effect of HDACi on IκBα protein expression in myometrial cells was therefore examined. Cells were pre-incubated with 500 nM TSA for 1 h and subsequently stimulated with IL-1β for 15 min, 2 h, 4 h, 8 h and 24 h. In cells treated with IL-1β alone, IκBα was completely degraded by 15 min post stimulation and resynthesized by 2 h (Fig. 3A). In cells pre-treated with TSA, IκBα degradation occurred as normal but resynthesized IκBα protein levels were markedly reduced at every time point post-stimulation. The reduction in IκBα levels was associated with a concomitant increase in nuclear levels of p65 at early time points (Fig. 3A). In cells treated for 8 h or 24 h with TSA and IL-1β, nuclear p65 expression did not differ from cells treated with IL-1β alone, while IκBα levels were still comparatively lower.

Like IκBα, IκBε can shuttle between the nucleus and cytoplasm and may participate in post-induction repression of NF-κB (Lee and Hannink, 2002). Therefore, the question of whether

TSA-induced changes in I κ B ϵ protein levels might contribute to the potentiation of NF- κ B at early time points and/or the inhibition of NF- κ B DNA binding at later times was also addressed. In cells treated with IL-1 β alone, I κ B ϵ was degraded 15 min post stimulation and resynthesized by 4 h (Fig. 3A). In cells pre-treated with TSA, I κ B ϵ degradation occurred as normal but resynthesized I κ B ϵ protein levels were reduced at 4 h post stimulation. However, unlike I κ B α , the repressive effect of TSA on I κ B ϵ did not persist, with I κ B ϵ protein levels returning to normal post-induction levels by 8 h (Fig. 3A).

I κ B β proteins also sequester a substantial proportion of NF- κ B dimers. Unlike I κ B α and I κ B ϵ , however, I κ B β does not exhibit nucleo-cytoplasmic shuttling, and does not contribute to post-induction termination of the NF- κ B response, since it lacks an NES (Huang and Miyamoto, 2001; Malek et al., 2001). Conversely, some studies have described a role for I κ B β in persistence of the NF- κ B response, either as a result of continual I κ B β turnover creating an imbalance in the relative levels of NF- κ B and I κ B proteins (Xu et al., 2006), or as a result of resynthesized nuclear I κ B β acting in a chaperone-like fashion to prevent the nuclear export of NF- κ B by I κ B α (DeLuca et al., 1999). However, we found that, in myometrial cells, I κ B β is resynthesized with delayed kinetics in the presence of IL- β alone, and does not contribute to the persistence of NF- κ B activation (Fig. 3A and unpublished data). Furthermore, TSA had no effect on the IL-1 β -induced degradation or resynthesis of I κ B β (Fig. 3A).

The heterodimeric importin α/β complex is responsible for the nuclear import of proteins containing nuclear localisation signals (NLSs), and importin α is subject to dynamic acetylation

(Bannister et al., 2000). The second ankyrin repeat of I κ B α serves as a substitute for a classical NLS and nuclear import of I κ B α requires both importin α and importin β (Turpin et al., 1999). I κ B ϵ likely utilises a similar mechanism to I κ B α to enter the cell nucleus (Lee and Hannink, 2002). We therefore asked whether HDACi prolong the nuclear localisation of NF- κ B at early time points by disrupting the nuclear import of resynthesized I κ B α or I κ B ϵ . Cytosolic and nuclear fractions of myometrial cells treated with TSA +/- IL-1 β were assessed for levels of I κ B α and I κ B ϵ proteins. I κ B α and I κ B ϵ proteins were detected in both the cytoplasmic and the nuclear fractions under basal conditions, although nuclear I κ B ϵ levels were low (Fig. 3B), consistent with previous work showing that nuclear import of I κ B ϵ is less efficient than that of I κ B α (Lee and Hannink, 2002). Stimulation of myometrial cells with IL-1 β for 15 min resulted in the degradation of both cytoplasmic and nuclear I κ B α and I κ B ϵ proteins (Fig. 3B). Treatment of cells with TSA alone did not result in accumulation of I κ B proteins in the cytosol (Fig. 3B). Similarly, the ratio of cytosolic:nuclear levels of resynthesized I κ B proteins was not greater in cells treated with IL-1 β plus TSA compared to cells treated with IL-1 β alone (Fig. 3C). This suggests that the HDACi-induced prolongation of NF- κ B nuclear localisation at early time points is not due to disrupted import of inhibitory I κ B proteins.

Both I κ B α and I κ B ϵ require the chromosome maintenance 1 (CRM1)-dependent nuclear export pathway to exit the nucleus and restore cytosolic pools of NF- κ B (Huang and Miyamoto, 2001; Lee and Hannink, 2002). Since there was also no difference in the ratio of nuclear:cytosolic levels of resynthesized I κ B proteins between cells treated with IL-1 β plus TSA and cells treated with IL-1 β alone at early time points (Fig. 3C), it appears that the HDACi-induced prolongation

of NF- κ B nuclear localisation at early time points is not due a failure to export I κ B-bound NF- κ B from the nucleus. As seen above (Fig. 1A-E), long-term exposure (>6 h) of myometrial cells to TSA results in inhibition of IL-1 β -induced NF- κ B DNA binding independently of effects on nuclear levels of NF- κ B. Such inhibition could potentially reflect a scenario in which NF- κ B is dissociated from DNA by I κ B α/ϵ , but cannot be exported to the cytoplasm due to delayed disruption of the CRM1 export pathway. However, we also failed to detect any difference in the ratio of nuclear:cytosolic levels of resynthesized I κ B proteins between cells treated with IL-1 β plus TSA and cells treated with IL-1 β alone at late time points (Fig. 3C), indicating that CRM1-mediated export is not targeted by TSA.

Taken together, these findings suggest that HDACi prolong NF- κ B nuclear localisation and DNA binding following IL-1 β stimulation by decreasing the levels of resynthesized I κ B α and I κ B ϵ proteins, but not by disrupting the nuclear import/export of NF- κ B/I κ B complexes. It appears that the secondary, inhibitory effects of HDACi on NF- κ B DNA binding are not related to changes in I κ B α or I κ B ϵ protein levels, but rather target NF- κ B downstream of its release from I κ B proteins.

HDACi do not inhibit I κ B α mRNA expression

We next sought to examine the effect of HDACi on I κ B α expression in more detail. As with TSA, pre-treatment of myometrial cells for 1 h with SAHA also resulted in decreased I κ B α protein levels 2 h after IL-1 β stimulation (Fig. 4A). The cytosolic lysates corresponding to the nuclear lysates used in the chase experiment for NF- κ B were next probed for levels of I κ B α

protein. Converse to the findings for NF- κ B, I κ B α protein levels were decreased in cells incubated with TSA following a transient stimulation with IL-1 β (Fig. 4B, *compare lanes 3-5 with lanes 6-8*). To determine whether administration of HDACi after the initial degradation of I κ B α would have the same effect as pre-incubation of cells with HDACi, TSA was added to myometrial cells 1 h after the addition of IL-1 β , and this also resulted in marked reduction of I κ B α protein expression at 2 h after IL-1 β stimulation (Fig. 4C). At 1 h post-IL-1 β stimulation, I κ B α protein has already been resynthesized in these cells, but continual I κ B α protein synthesis is needed to sustain the concentration of I κ B α throughout the course of the stimulation (unpublished data). We therefore investigated whether the inhibition of I κ B α protein expression in IL-1 β -stimulated myometrial cells by TSA occurred at the level of transcription/mRNA stability, as recently reported for pervanadate-stimulated HeLa cells (Horion et al., 2007). To assess the effects of HDACi on transcription of the *IKBA* gene and/or I κ B α mRNA stability, I κ B α mRNA expression was analysed by real-time PCR in myometrial cells pre-incubated for 1 h with 500 nM TSA or 5 μ M SAHA and stimulated with IL-1 β for the indicated times. IL-1 β induction of I κ B α mRNA expression was detected as early as 15 min and peaked at 2 h (Fig. 4D). TSA alone had no effect on I κ B α mRNA expression. However, TSA treatment resulted in a modest increase in IL-1 β -stimulated I κ B α mRNA expression at 2 h and 4 h, which was lost at later time points (Fig. 4D). Similar results were obtained with SAHA (data not shown). These findings indicate that HDACi do not decrease I κ B α protein levels by impairing the transcriptional activation of the *IKBA* promoter or decreasing I κ B α mRNA stability, and that they likely reduce I κ B α expression by targeting the stability of the protein. In addition, the

HDACi-induced augmentation of IL-1 β -induced I κ B α mRNA expression is consistent with the observed potentiation of NF- κ B by HDACi, since *IKBA* transcription is driven by NF- κ B.

HDACi potentiate IKK β activity

Degradation of I κ B α protein is carried out by the 26S proteasome, for which phosphorylation by IKK β on serines 32 and 36 is a prerequisite (Traenckner et al., 1995). We therefore examined whether enhanced IKK β activity could account for the reduction in I κ B α protein levels in the presence of TSA plus IL-1 β . Endogenous IKK β was immunoprecipitated from myometrial cells treated with IL-1 β , TSA or IL-1 β plus TSA, and IKK β kinase activity was assayed by using a GST-I κ B α fusion protein as substrate and visualizing its phosphorylation by Western immunoblotting with an antibody that recognizes I κ B α phosphorylated on serines 32 and 36. As expected, IL-1 β caused an induction of IKK β activity, which peaked at 15 min and was still detectable but much reduced at 2 h, at which time I κ B α protein was resynthesized (Fig. 5A). Cells pre-incubated with TSA for 1 h exhibited increased IKK β activity at 2 h of IL-1 β stimulation compared with cells treated with IL-1 β alone. The increase in IKK β activity was associated with a decrease in levels of resynthesized I κ B α . Similar findings were reported in TNF α -stimulated HeLa cells (Adam et al., 2003). Thus, enhanced/prolonged IKK β activity leading to persistent degradation of resynthesized I κ B α (and I κ B ϵ) likely underlies the prolonged nuclear localisation of NF- κ B in the presence of IL-1 β and HDACi.

Several distinct kinases have been reported to phosphorylate p65 at serine 536 (Ser536), a modification that plays an important role in the subsequent acetylation of this protein and in NF-

κ B transcriptional activity (Buss et al., 2004; Hoberg et al., 2006). While pharmacological inhibition of RSK1 or p38 had no effect on IL-1 β -induced phosphorylation of p65 at Ser536 in myometrial cells (data not shown), such phosphorylation was abrogated in both the cytoplasm and the nucleus by the selective IKK β inhibitor sc-514 (Fig. 5B). Thus, since IKK β mediates the Ser536-phosphorylation of p65 in response to IL-1 β stimulation, the augmentation of IKK β activity by TSA could result in the prolonged phosphorylation of p65 at this residue. On examination of whole-cell lysates, levels of Ser536-phosphorylated p65 were found to be greater in cells treated with TSA plus IL-1 β compared to cells treated with IL-1 β alone at the 4 h and 8 h time points, while total p65 protein expression was not affected by either treatment (Fig. 5C).

Therefore, HDACi-induced potentiation of IKK β activity can enhance NF- κ B activity via the prolongation of NF- κ B nuclear localisation as well as via the posttranslational modification of the p65 NF- κ B subunit.

Both short- and long-term exposure to HDACi represses COX-2, IL-6, IL-8 and RANTES expression, and inhibits the c-Jun and C/EBP transcription factors

The pro-inflammatory genes encoding interleukin (IL)-6, IL-8, regulated-upon-activation normal-T-cell-expressed and -secreted (RANTES), and cyclo-oxygenase-2 (COX-2) have all been implicated in human parturition and contain NF- κ B recognition elements in their promoters (Lindstrom and Bennett, 2005b). The outcome of HDACi administration on the expression of endogenous NF- κ B target genes cannot be predicted from the *in vitro* data on NF- κ B. The transient reporter assays described should reflect primary and secondary effects of HDACi on the NF- κ B signalling pathway but do not reflect potential effects on histone modifications since

transiently transfected plasmids are not efficiently packaged into chromatin (Hebbar and Archer, 2008). Furthermore, since multiple signalling pathways may be targeted by HDACi to affect transcription of NF- κ B target genes in a promoter-specific manner, the effect of HDACi on specific NF- κ B-regulated genes must be empirically determined.

The effect of exposure of myometrial cells to HDACi on the expression the four labour-associated genes, *COX-2*, *IL-6*, *IL-8* and *RANTES*, was therefore examined. Since long-term exposure to HDACi may produce differential primary and secondary effects on inflammatory gene expression (Suuronen et al., 2006), mRNA expression of these genes was examined following both short- and long-term treatments with HDACi plus IL-1 β . Real-time PCR analysis was performed on RNA isolated from myometrial cells pre-incubated with TSA for 1 h, and stimulated with IL-1 β for 15 min, 2 h, 4 h, 8 h, and 24 h. IL-1 β induced COX-2 mRNA expression by 2 h, which declined progressively from 4-24 h (Fig. 6). IL-1 β -stimulated IL-6 mRNA was detected at 2 h and remained at maximal levels from 2-8 h, exhibiting a slight decrease at 24 h. IL-8 expression was induced by 2 h, remaining elevated up to 24 h. IL-1 β induced RANTES expression by 2 h, which was maximal at 8h and 24 h. TSA alone had no effect on expression of any of the genes at any time point, indicating that the *COX-2*, *IL-6*, *IL-8*, and *RANTES* are not repressed by class I/II HDACs under basal conditions. However, TSA inhibited IL-1 β -induced expression of COX-2, IL-6, IL-8, and RANTES mRNA at all time points (Fig. 6). Similar results were obtained with SAHA (data not shown). Western immunoblot analysis of lysates from myometrial cells pre-treated with TSA for 1 h followed by IL-1 β stimulation over a 24 h period confirmed inhibition of COX-2 expression by TSA at the protein level, which was observed at both early and late time points (Fig. 7A). SAHA was also found to

inhibit COX-2 protein expression following IL-1 β stimulation (Fig. 7B). Thus, these findings demonstrate that both short-term and long-term inhibition of class I and II HDAC activities represses the expression of key pro-inflammatory genes involved in human parturition.

The observed inhibitory effect of HDACi on the expression of *COX-2*, *IL-6*, *IL-8* and *RANTES* genes is in contrast to the positive effects of HDACi on NF- κ B activity and *IKBA* transcription at early time points. Transcriptional activation of these genes requires the coordinated action of multiple transcription factors, and the activity of pro-inflammatory activators other than NF- κ B may be negatively regulated by acetylation. Apart from NF- κ B, the pro-inflammatory transcription factor c-Jun is also required for the transcription of *COX-2*, *IL-6*, *IL-8* and *RANTES* in many cell types (Saccani et al., 2001). We therefore examined the effects of HDACi on c-Jun in myometrial cells. Western immunoblot analysis of lysates from myometrial cells pre-treated with TSA for 1 h followed by IL-1 β stimulation over a 24 h period showed that TSA decreased IL-1 β -induced nuclear levels of c-Jun at both early and late time points. SAHA was also shown to reduce nuclear c-Jun levels following IL-1 β stimulation (Fig. 7B). The HDACi-induced reduction in nuclear levels of c-Jun was found to be due, at least in part, to decreased expression of c-Jun protein (Fig. 7C).

Thus, both short- and long-term exposure of myometrial cells to HDACi inhibits the pro-inflammatory transcription factors c-Jun, and suppresses the expression of key labour-associated genes.

Discussion

HDACi are in clinical trials for the treatment of inflammatory disorders (Bolden et al., 2006; Luhrs et al., 2002) and recent evidence suggests that they may also have therapeutic potential in the management of preterm labour (Condon et al., 2003; Mitchell, 2006; Phillips et al., 2005). Since NF- κ B is a key orchestrator of the inflammatory response and plays a pivotal role in parturition, it is important to understand how administration of HDACi might affect NF- κ B activity in human uterine tissues. In the present study, we show that HDACi exert time-dependent effects on NF- κ B activity in primary human myometrial cells. Whereas short-term treatment with HDACi resulted in the prolongation of IL-1 β -stimulated NF- κ B DNA binding and the augmentation of NF- κ B transcriptional activity, long-term treatment reduced IL-1 β -stimulated NF- κ B DNA binding. Thus, although some of the discrepancies between studies regarding the effects of HDACi on NF- κ B may be due to cell type-specific differences, it appears that a certain proportion might be attributable to differences in experimental protocol.

HDACi alone did not induce NF- κ B activity in myometrial cells, but acted to enhance the stimulatory effects of IL-1 β , even after IL-1 β was withdrawn. This implies that a stimulus is required for the initial activation and acetylation of NF- κ B pathway components, while HDACi prolong such acetylation, and thereby prolong NF- κ B activity. The primary, positive effects of HDACi on NF- κ B activity were shown to be due, at least in part, to the suppression of I κ B α and I κ B ϵ protein reappearance following stimulus-induced degradation. This was a consequence of the augmentation of IL-1 β -induced IKK β activity by HDACi, leading to the persistent turnover of I κ B α/ϵ . Since I κ B α (Huang and Miyamoto, 2001), and possibly I κ B ϵ (Lee and Hannink,

2002), mediate the post-induction shut-off on the NF- κ B response, the absence of these critical inhibitors of NF- κ B resulted in sustained NF- κ B nuclear localisation and DNA binding, which translated to an increase in NF- κ B transcriptional activity.

The observed effects of HDACi may also reflect changes in posttranslational modification of NF- κ B itself. IKK β was found to mediate IL-1 β -induced phosphorylation of p65 at Ser536, an important determinant of subsequent p65 acetylation and NF- κ B transcriptional activity (Buss et al., 2004; Hoberg et al., 2006), and such phosphorylation was augmented by TSA. Thus, the HDACi-induced potentiation of IKK β activity might additionally enhance NF- κ B activity independently of effects on NF- κ B DNA binding, via the prolongation of p65 Ser536 phosphorylation and associated acetylation. HDACi could also, however, modulate NF- κ B signalling via direct effects on the acetylation status of NF- κ B subunits, i.e. by blocking their deacetylation. Acetylation of p65 at lysine 221 has been shown to enhance its binding to DNA and impair its assembly with I κ B α , while acetylation at lysine 310 promotes p65 transcriptional activity (Chen et al., 2001; Chen and Greene, 2003). DNA binding of p50 may also be enhanced by acetylation (Furia et al., 2002).

The inhibitory effects of HDACi on NF- κ B observed at later time points are likely to be indirect, involving broader changes in cell physiology and possibly resulting from changes in protein synthesis, since this would require more time than changes in the activity of a latent transcription factor. Studies in other cell types have shown that many of the effects of HDACi on gene transcription are lost if translation is inhibited (Reid et al., 2005). In cancer cells, inhibition of TNF α -induced NF- κ B by HDACi occurs as a function of decreased I κ B α degradation, due

MOL #42838

either to repression of proteasome activity (Place et al., 2005) or repression of IKK activation (Takada et al., 2006). These mechanisms cannot account for the delayed repression of NF- κ B in myometrial cells, however, since the inhibitory effects of HDACi on NF- κ B DNA binding were not related to an increase in I κ B protein levels, indicating that the inhibitory actions of HDACi must target NF- κ B downstream of its release from I κ B α .

Since HH4 acetylation is observed in myometrial cells after short-term but not long-term exposure to HDACi, as is also observed in other cell types (Ajamian et al., 2004; Waterborg and Kapros, 2002), it is possible that that TSA is intra-cellularly metabolised to an inactive form within a few hours. However, TSA is still able to inhibit the mRNA expression of IL-6, IL-8 and RANTES at 24 h. This could be because the downstream effects of TSA have not yet been reversed. On the other hand, the loss of detectable HH4 acetylation, as well as the secondary effects of HDACi on NF- κ B, could also be due to a shift in the cellular acetylation/deacetylation balance, resulting from autoregulatory feedback loops that impact on HDAC (Ajamian et al., 2004; Waterborg and Kapros, 2002) or HAT (Covault et al., 1982) activity. Differential regulation by HDACi of distinct HDAC isoforms that impact on different activities of NF- κ B (Chen and Greene, 2003; Kyrylenko et al., 2003; Yeung et al., 2004) could explain the observation that NF- κ B transcriptional activity is modestly potentiated in the face of decreased NF- κ B DNA binding following long-term exposure to HDACi plus IL-1 β .

The observed effects of HDACi on NF- κ B activity *per se* represent global effects on NF- κ B in myometrial cells and indicate changes in the potential of NF- κ B to drive inflammation. Effects of HDACi on gene expression, on the other hand, are promoter-specific, and hence must be

empirically determined. In addition to effects on the activity of NF- κ B, HDAC inhibition can exert effects on chromatin structure surrounding an NF- κ B target promoter, and may also differentially modulate the expression or activity of distinct transcription factors that cooperate in the transcriptional induction of a given gene. Thus, it is not surprising that the effects of HDACi on NF- κ B do not always correlate with their effects on the expression of NF- κ B target genes. Indeed we found that, in myometrial cells, both TSA and SAHA inhibited the expression of COX-2, IL-8, IL-6 and RANTES mRNA under conditions in which they enhanced NF- κ B activity, suggesting that effects on this transcription factor are unlikely to underlie the inhibition of COX-2, IL-6, IL-8, and RANTES expression by HDACi. In addition, since HDACi were shown to induce H4 acetylation, and histone acetylation is known to facilitate transcriptional induction, effects of HDACi on local chromatin conformation are not likely to account for the inhibition of these genes. Rather, the anti-inflammatory effects of HDACi may be due to the inhibition of pro-inflammatory pathways other than the NF- κ B pathway. Indeed, we show here that HDACi reduced the expression of c-Jun, in agreement with previous studies showing that TSA inhibits c-Jun expression by blocking the recruitment of RNA polymerase II to the *c-jun* promoter (Yamaguchi et al., 2005). c-Jun is essential for the transcriptional induction of IL-6, COX-2 and RANTES genes in many cell types (Saccani et al., 2001; Wu, 2005). Thus, inhibition of c-Jun could potentially account for some of the anti-inflammatory effects of HDACi in myometrial cells.

Condon and colleagues have suggested that a global decrease in HAT activity within the myometrium leads to the initiation of labour by reducing progesterone receptor activity at the promoters of genes that maintain uterine quiescence (Condon et al., 2003), while exposure of

myometrial cells to TSA has been shown to up-regulate the expression of the chorionic gonadotrophin/luteinizing hormone receptor (Phillips et al., 2005), a receptor that signals to increase levels of the smooth muscle relaxant cAMP. On the other hand, we show here that HDACi inhibit the expression, in human myometrium, of several key pro-inflammatory genes implicated in parturition, suggesting that at least a proportion of the impact of decreased HAT and/or increased HDAC activity on uterine contractility at term may result from the stimulation or de-repression of pro-inflammatory gene expression. Taken together, these findings indicate that HDACi administration may lead to a myometrial gene expression profile that favours uterine quiescence, both by inhibiting pro-inflammatory pathways and by de-repressing pathways that promote uterine relaxation, and suggest that these compounds could have therapeutic potential in the management of preterm labour.

Although HDACi did not increase the expression of the endogenous NF- κ B-regulated genes examined in the present study, it remains possible that the expression of NF- κ B-dependent genes, whose induction does not involve activators that are negatively regulated by acetylation (e.g., c-Jun) will be up-regulated by HDACi. Combining HDACi with an NF- κ B inhibitor, as has been done in clinical trials for cancer treatment (Bolden et al., 2006), should negate any undesirable effects resulting from potentiation of NF- κ B activity at early time points, and data presented here suggest that an IKK β inhibitor should be efficacious in this regard. HDACi-induced inhibition of c-Jun, on the other hand, might be expected to additionally suppress the expression of other pro-inflammatory or labour-associated genes that are not NF- κ B-regulated. The ideal tocolytic HDACi compound should target the specific HDAC isoforms that are expressed in uterine tissues in association with labour onset, and efforts to develop more

MOL #42838

selective HDACi compounds are currently a major focus of research into the therapeutic use of HDACi (Kelly and Marks, 2005).

References

- Adam E, Quivy V, Bex F, Chariot A, Collette Y, Vanhulle C, Schoonbroodt S, Goffin V, Nguyen TL, Gloire G, Carrard G, Friguet B, De Launoit Y, Burny A, Bours V, Piette J and Van Lint C (2003) Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. *Mol Cell Biol* **23**(17):6200-6209.
- Ajamian F, Salminen A and Reeben M (2004) Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells. *Neurosci Lett* **365**(1):64-68.
- Bannister AJ, Miska EA, Gorlich D and Kouzarides T (2000) Acetylation of importin-alpha nuclear import factors by CBP/p300. *Curr Biol* **10**(8):467-470.
- Bolden JE, Peart MJ and Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov* **5**(9):769-784.
- Buss H, Dorrie A, Schmitz ML, Hoffmann E, Resch K and Kracht M (2004) Constitutive and interleukin-1-inducible phosphorylation of p65 NF- κ B at serine 536 is mediated by multiple protein kinases including I κ B kinase (IKK)- α , IKK β , IKK ϵ , TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. *J Biol Chem* **279**(53):55633-55643.
- Chen L, Fischle W, Verdin E and Greene WC (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. *Science* **293**(5535):1653-1657.
- Chen LF and Greene WC (2003) Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. *J Mol Med* **81**(9):549-557.
- Condon JC, Jeyasuria P, Faust JM, Wilson JW and Mendelson CR (2003) A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. *Proc Natl Acad Sci U S A* **100**(16):9518-9523.
- Covault J, Sealy L, Schnell R, Shires A and Chalkley R (1982) Histone hypoacetylation following release of HTC cells from butyrate. *J Biol Chem* **257**(10):5809-5815.
- DeLuca C, Petropoulos L, Zmeureanu D and Hiscott J (1999) Nuclear I κ B β maintains persistent NF-kappaB activation in HIV-1-infected myeloid cells. *J Biol Chem* **274**(19):13010-13016.
- Elliott CL, Loudon JA, Brown N, Slater DM, Bennett PR and Sullivan MH (2001) IL-1 β and IL-8 in human fetal membranes: changes with gestational age, labor, and culture conditions. *Am J Reprod Immunol* **46**(4):260-267.
- Francis J, Rai R, Sebire NJ, El-Gaddal S, Fernandes MS, Jindal P, Lokugamage A, Regan L and Brosens JJ (2006) Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. *Mol Hum Reprod* **12**(7):435-442.
- Furia B, Deng L, Wu K, Baylor S, Kehn K, Li H, Donnelly R, Coleman T and Kashanchi F (2002) Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins. *J Biol Chem* **277**(7):4973-4980.

- Hebbar PB and Archer TK (2008) Altered histone h1 stoichiometry and an absence of nucleosome positioning on transfected DNA. *J Biol Chem* **283**(8):4595-4601.
- Hoberg JE, Popko AE, Ramsey CS and Mayo MW (2006) IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. *Mol Cell Biol* **26**(2):457-471.
- Horion J, Gloire G, El Mjiyad N, Quivy V, Vermeulen L, Vanden Berghe W, Haegeman G, Van Lint C, Piette J and Habraken Y (2007) Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappaB activation by delaying IkappaBalpha mRNA resynthesis: comparison with tumor necrosis factor alpha. *J Biol Chem* **282**(21):15383-15393.
- Huang TT and Miyamoto S (2001) Postrepression activation of NF-kappaB requires the amino-terminal nuclear export signal specific to IkappaBalpha. *Mol Cell Biol* **21**(14):4737-4747.
- Kelly WK and Marks PA (2005) Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. *Nat Clin Pract Oncol* **2**(3):150-157.
- Kyrylenko S, Kyrylenko O, Suuronen T and Salminen A (2003) Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. *Cell Mol Life Sci* **60**(9):1990-1997.
- Lee SH and Hannink M (2002) Characterization of the nuclear import and export functions of Ikappa B(epsilon). *J Biol Chem* **277**(26):23358-23366.
- Li YJ, Fu XH, Liu DP and Liang CC (2004) Opening the chromatin for transcription. *Int J Biochem Cell Biol* **36**(8):1411-1423.
- Lindstrom TM and Bennett PR (2005a) 15-Deoxy- $\Delta^{12,14}$ -prostaglandin j2 inhibits interleukin-1 β -induced nuclear factor- κ b in human amnion and myometrial cells: mechanisms and implications. *J Clin Endocrinol Metab* **90**(6):3534-3543.
- Lindstrom TM and Bennett PR (2005b) The role of nuclear factor kappa B in human labour. *Reproduction* **130**(5):569-581.
- Luhrs H, Gerke T, Muller JG, Melcher R, Schaubert J, Boxberge F, Scheppach W and Menzel T (2002) Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. *Scand J Gastroenterol* **37**(4):458-466.
- Malek S, Chen Y, Huxford T and Ghosh G (2001) IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. *J Biol Chem* **276**(48):45225-45235.
- Mattioli I, Sebald A, Bucher C, Charles RP, Nakano H, Doi T, Kracht M and Schmitz ML (2004) Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import. *J Immunol* **172**(10):6336-6344.
- Mendelson CR and Condon JC (2005) New insights into the molecular endocrinology of parturition. *J Steroid Biochem Mol Biol* **93**(2-5):113-119.
- Mitchell MD (2006) Unique suppression of prostaglandin H synthase-2 expression by inhibition of histone deacetylation, specifically in human amnion but not adjacent choriodecidua. *Mol Biol Cell* **17**(1):549-553.
- Phillips RJ, Tyson-Capper Nee Pollard AJ, Bailey J, Robson SC and Europe-Finner GN (2005) Regulation of expression of the chorionic gonadotropin/luteinizing hormone receptor gene in the human myometrium: involvement of specificity protein-1 (Sp1), Sp3, Sp4, Sp-like proteins, and histone deacetylases. *J Clin Endocrinol Metab* **90**(6):3479-3490.

- Place RF, Noonan EJ and Giardina C (2005) HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. *Biochem Pharmacol* **70**(3):394-406.
- Quivy V and Van Lint C (2004) Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. *Biochem Pharmacol* **68**(6):1221-1229.
- Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET and Gannon F (2005) Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. *Oncogene* **24**(31):4894-4907.
- Romero R, Tarca AL and Tromp G (2006) Insights into the physiology of childbirth using transcriptomics. *PLoS Med* **3**(6):e276.
- Saccani S, Pantano S and Natoli G (2001) Two waves of nuclear factor kappaB recruitment to target promoters. *J Exp Med* **193**(12):1351-1359.
- Suuronen T, Huuskonen J, Nuutinen T and Salminen A (2006) Characterization of the pro-inflammatory signaling induced by protein acetylation in microglia. *Neurochem Int* **49**(6):610-618.
- Takada Y, Gillenwater A, Ichikawa H and Aggarwal BB (2006) Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. *J Biol Chem* **281**(9):5612-5622.
- Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S and Baeuerle PA (1995) Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. *Embo J* **14**(12):2876-2883.
- Turpin P, Hay RT and Dargemont C (1999) Characterization of IkappaBalpha nuclear import pathway. *J Biol Chem* **274**(10):6804-6812.
- Vadillo-Ortega F, Sadowsky DW, Haluska GJ, Hernandez-Guerrero C, Guevara-Silva R, Gravett MG and Novy MJ (2002) Identification of matrix metalloproteinase-9 in amniotic fluid and amniochorion in spontaneous labor and after experimental intrauterine infection or interleukin-1 beta infusion in pregnant rhesus monkeys. *Am J Obstet Gynecol* **186**(1):128-138.
- Wan Y, Saghatelian A, Chong LW, Zhang CL, Cravatt BF and Evans RM (2007) Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. *Genes Dev* **21**(15):1895-1908.
- Waterborg JH and Kapros T (2002) Kinetic analysis of histone acetylation turnover and Trichostatin A induced hyper- and hypoacetylation in alfalfa. *Biochem Cell Biol* **80**(3):279-293.
- Wen SW, Smith G, Yang Q and Walker M (2004) Epidemiology of preterm birth and neonatal outcome. *Semin Fetal Neonatal Med* **9**(6):429-435.
- Wu KK (2005) Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. *Prostaglandins Leukot Essent Fatty Acids* **72**(2):89-93.
- Xu S, Bayat H, Hou X and Jiang B (2006) Ribosomal S6 kinase-1 modulates interleukin-1beta-induced persistent activation of NF-kappaB through phosphorylation of IkappaBbeta. *Am J Physiol Cell Physiol* **291**(6):C1336-1345.
- Yamaguchi K, Lantowski A, Dannenberg AJ and Subbaramaiah K (2005) Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. *J Biol Chem* **280**(38):32569-32577.

MOL #42838

Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA and Mayo MW (2004)
Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1
deacetylase. *Embo J* **23**(12):2369-2380.

Footnotes

This work was supported by Tommy's Campaign

*To whom reprint requests should be addressed: Tamsin Lindstrom, 3rd Floor IRDB, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK.

Email: tamsinlindstrom@gmail.com

Legends for figures

Figure 1. Time-dependent effects of HDACi on NF- κ B activity.

(A) Myometrial cells were pre-incubated with the indicated concentrations of TSA for 1 h, and then stimulated with IL-1 β (1 ng/ml) for 2 h or 24 h, and nuclear lysates were assessed by EMSA for NF- κ B DNA binding using a consensus κ B probe. 100-fold excess of unlabelled κ B (xs spec) or irrelevant (xs nonspec) oligonucleotide was added to lanes 7 and 8, respectively, prior to the addition of [³²P]-labelled probe as DNA binding competitor to verify specificity of binding. (B) Densitometric quantitation of p50/p65 and p50/p50 DNA-binding complexes normalised against actin protein levels. Data are presented as fold induction relative to non-stimulated cells at the start of the experiment, and are the mean \pm SEM from two independent experiments. The bars representing TSA or TSA + IL1 β bands reflect data from cells incubated with 500 nM TSA (C) Myometrial cells were pre-incubated with 5 μ M SAHA for 1 h, and then stimulated with IL-1 β (1 ng/ml) for 2 h or 24 h, and nuclear lysates were assessed by EMSA for NF- κ B DNA binding using a consensus κ B probe. We have previously identified the NF- κ B complexes binding to DNA in response to IL-1 β in myometrial cells as p65/p65, p50/p50, and p50/p65 at early time points, and p50/p50, and p50/p65 at late time points (Lindstrom and Bennett, 2005a and unpublished data), as indicated. (D) Nuclear lysates from (A) were assessed for expression of acetylated HH4 (ac-HH4) by Western immunoblotting. (E) Myometrial cells were pre-incubated with the indicated concentrations of TSA for 1 h, and then stimulated with IL-1 β (1 ng/ml) for 6 h, and nuclear lysates were assessed by EMSA for NF- κ B DNA binding using a consensus κ B probe. 100-fold excess of unlabelled κ B (xs spec) or irrelevant (xs nonspec) oligonucleotide was added to lanes 7 and 8, respectively. (F) Densitometric quantitation of p50/p65 and p50/p50

DNA-binding complexes normalised against actin protein levels. Data are presented as fold induction relative to non-stimulated cells at the start of the experiment, and are the mean \pm SEM from two independent experiments. The bars representing TSA or TSA + IL1 β bands reflect data from cells incubated with 500 nM TSA. (G) Myometrial cells were transiently transfected with 0.4 μ g/well of an NF- κ B-dependent luciferase reporter (NF- κ B-LUC), pre-treated for 1 h with 500 nM TSA, followed by stimulation with IL-1 β (1 ng/ml) for 4 h or 24 h. NF- κ Bmut-LUC, in which the κ B sites are mutated, was used as a control to confirm NF- κ B-mediated transactivation. Cells were co-transfected with a CMV-renilla reporter plasmid as an internal control, and luciferase activity normalized for renilla reporter readout. Results are the mean \pm SEM from three independent experiments performed in triplicate, and are presented as the fold induction relative to reporter activity in cells treated with vehicle only at 4 h.

Figure 2. Short-term exposure to HDACi prolongs NF- κ B nuclear localisation and DNA binding in response to IL-1 β .

(A) Myometrial cells were pre-incubated with 500 nM TSA for 1 h, and then stimulated with IL-1 β (1 ng/ml) for 15 min, 2 h or 4 h, and nuclear lysates were assessed by EMSA for NF- κ B DNA binding using a consensus κ B probe. 100-fold excess of unlabelled κ B (xs spec) or irrelevant (xs nonspec) oligonucleotide was added to lanes 10 and 11, respectively, prior to the addition of [32P]-labelled probe as DNA binding competitor to verify specificity of binding. (B) Densitometric quantitation of p65/p65, p50/p65 and p50/p50 DNA-binding complexes normalised against actin protein levels. Data are presented as fold induction relative to non-stimulated cells at the start of the experiment, and are the mean \pm SEM from three independent experiments. (C) Myometrial cells were pre-incubated with 100 nM or 500 nM TSA for 1 h, and

then stimulated with IL-1 β (1 ng/ml) for 2 h. Cytosolic and nuclear extracts were prepared and assessed for levels of p65 by Western immunoblotting. (D) Myometrial cells were pulse-stimulated with IL-1 β (1 ng/ml) for 15 min, the IL-1 β was then washed out and incubation continued for 1, 2, or 4 h in medium alone or in the presence of 500 nM TSA. Nuclear extracts were prepared and assessed by EMSA for NF- κ B DNA binding using a consensus κ B probe, and for nuclear levels of p65, p50 and acetylated HH4 (ac-HH4) proteins by Western immunoblotting.

Figure 3. HDACi reduce levels of resynthesized I κ B α and I κ B ϵ proteins following IL-1 β stimulation, but do not influence the cytosolic:nuclear ratio.

Myometrial cells were pre-incubated with 500 nM TSA for 1 h, then stimulated with IL-1 β (1 ng/ml) for the indicated times, and cytosolic/nuclear extracts were prepared. (A) Cytosolic I κ B α , I κ B ϵ and I κ B β protein levels, and nuclear p65 protein levels were assessed by Western immunoblotting. (B) & (C) Cytosolic and nuclear levels of I κ B α and I κ B ϵ were compared by Western immunoblotting. Blots were re-probed for lamin B expression to confirm the integrity of cell fractionation.

Figure 4. HDACi reduce resynthesized I κ B α protein levels, independently of effects on I κ B α mRNA expression.

(A) Myometrial cells were pre-incubated with 5 or 25 μ M SAHA for 1 h, and then stimulated with IL-1 β (1 ng/ml) for 2 h. Cytosolic and nuclear extracts were prepared and assessed by Western immunoblotting for protein levels of cytosolic I κ B α and nuclear acetylated HH4 (ac-HH4). (B) Myometrial cells were pulse-stimulated with IL-1 β (1 ng/ml) for 15 min, the IL-1 β

was then washed out and incubation continued for 1, 2, or 4 h in medium alone or in the presence of 500 nM TSA. Cytosolic extracts were prepared and assessed for I κ B α protein levels by Western immunoblotting. (C) Myometrial cells were either stimulated with IL-1 β alone (1 ng/ml) for 15 min or 2 h, or were incubated with 500 nM TSA for 12 h or 1 h prior to the addition of IL-1 β (12h pre or 1h pre), or had TSA added to them 1 h after the start of stimulation with IL-1 β (1h post). Cytosolic extracts were prepared and assessed for expression of I κ B α protein by Western immunoblotting. (D) Myometrial cells were pre-incubated with 500 nM TSA for 1 h and stimulated with IL-1 β (1 ng/ml) for the indicated times. Total RNA was isolated and mRNA expression of I κ B α was examined by real-time PCR. I κ B α mRNA values were normalised against expression levels of the *LI9* house-keeping gene. Data are presented as a percentage of the expression level at 4 h IL-1 β (the median time point, to allow inhibition by HDACi of IL-1 β -induced expression to be assessed in a background of patient-to-patient variation in degree of responsiveness to IL-1 β), and are the mean \pm SD from three independent experiments. * $p < 0.005$; ** $p < 0.0001$ (by unpaired t test, comparing IL-1 β vs TSA + IL-1 β at each time point). NT = non-treated.

Figure 5. TSA augments IL-1 β -induced IKK β activity.

(A) Myometrial cells were pre-incubated with 500 nM TSA for 1 h and stimulated with IL-1 β (1 ng/ml) for 15 min or 2 h, and whole-cell extracts were prepared. Endogenous IKK β was immunoprecipitated and IKK β kinase activity assayed using a GST-I κ B α fusion protein as substrate and visualizing its phosphorylation by Western immunoblotting with an antibody that recognizes I κ B α phosphorylated on serines 32 and 36 (Ser32/36-P-I κ B α). As negative controls,

lysates were immunoprecipitated with pre-immune rabbit IgG instead of IKK β antibody (*lane 6*) or IKK β antibody was incubated with protein sepharose A beads in the absence of cell lysate (*lane 7*). Membranes were re-probed with an antibody against IKK β to confirm the presence of equal immunoprecipitated IKK β , and the presence of equal GST-I κ B α substrate was verified by Western immunoblotting with an antibody against total I κ B α . Whole-cell extracts were also assessed for expression of endogenous I κ B α protein by Western immunoblotting. (B) Myometrial cells were pre-incubated for 1 h with 100 μ M sc-514 and then stimulated with IL-1 β (1 ng/ml) for 2 h. Cytosolic and nuclear extracts were prepared and assessed by Western immunoblotting for levels of serine 536-phosphorylated p65 (Ser536-p-p65). (C) Myometrial cells were pre-incubated with 500 nM TSA for 1 h and stimulated with IL-1 β (1 ng/ml) for the indicated times. Whole-cell extracts were assessed by Western immunoblotting for levels of Ser536-p-p65 and total p65.

Figure 6. Exposure of myometrial cells to TSA inhibits IL-1 β -induced mRNA expression of COX-2, IL-6, IL-8 and RANTES.

Myometrial cells were pre-incubated with 500 nM TSA for 1 h and stimulated with IL-1 β (1 ng/ml) for the indicated times. Total RNA was isolated and mRNA expression of (A) COX-2, (B) IL-6, (C) IL-8, and (D) RANTES was examined by real-time PCR. Values were normalised against expression levels of the *L19* house-keeping gene. Data are presented as a percentage of the expression level at 4 h IL-1 β (the median time point, to allow inhibition by HDACi of IL-1 β -induced expression to be assessed in a background of patient-to-patient variation in degree of responsiveness to IL-1 β), and are the mean \pm SD from three independent experiments. *

$p < 0.005$; ** $p < 0.0001$ (by unpaired t test, comparing IL-1 β vs TSA + IL-1 β at each time point).

NT = non-treated.

Figure 7. Inhibition of COX-2 expression by HDACi is associated with reduced c-Jun expression.

Myometrial cells were pre-incubated with 500 nM TSA for 1 h, and then stimulated with IL-1 β (1 ng/ml) for the indicated times. Cytosolic and nuclear extracts were prepared and assessed by Western immunoblotting for levels of cytosolic COX-2 protein and nuclear c-Jun and C/EBP β proteins. (B) Myometrial cells were pre-incubated with 5 μ M or 25 μ M SAHA or 500 nM TSA for 1 h, and then stimulated with IL-1 β (1 ng/ml) for 2 h. Cytosolic and nuclear extracts were prepared and assessed by Western immunoblotting for levels of cytosolic COX-2 and nuclear c-Jun proteins. (C) Myometrial cells were pre-incubated with 500 nM TSA for 1 h, and then stimulated with IL-1 β (1 ng/ml) for 15 min or 2 h. Whole-cell extracts were prepared and assessed by Western immunoblotting for total c-Jun protein expression.

Figure 8. Schematic diagram of the proposed primary, potentiating effects of HDACi on the NF- κ B signalling pathway.

(A) Acetylation/deacetylation modifications can modulate multiple steps in the NF- κ B pathway. Targets of HAT-mediated acetylation include IKK and the NF- κ B subunits themselves. Acetylation of IKK, or of an activating kinase upstream of IKK, promotes IKK activity following IL-1 β stimulation, thereby promoting I κ B α degradation and NF- κ B nuclear localisation/DNA binding. IKK-mediated phosphorylation of p65 also facilitates interaction of NF- κ B with the basal transcription machinery, as well as promoting p65 acetylation. Acetylation

MOL #42838

of p50 may enhance NF- κ B DNA binding, while acetylation of p65 may decrease association of NF- κ B with I κ B α and enhance NF- κ B DNA binding and transcriptional activity. HDACs act to oppose the activity of HATs by removing acetyl groups from proteins. Aside from being a target of acetylation/deacetylation, NF- κ B may also recruit HATs and HDACs to the promoters of target genes to regulate transcription by modulating local chromatin structure and recruitment of bromodomain-containing regulators of transcription. (B) Inhibition of HDAC activities by TSA or SAHA may thus augment NF- κ B signalling by prolonging and enhancing these acetylation modifications, leading to increased IKK activity, which results in increased I κ B degradation, thereby prolonging nuclear localisation and DNA binding of NF- κ B. Enhanced acetylation of p50 and p65 may also contribute to an increase in DNA binding and transcriptional activity of NF- κ B *per se*, while inhibition of the activities of HDACs at the promoters of NF- κ B target genes may enhance transcription independently of effects on NF- κ B. As shown in (A), an IKK β inhibitor (e.g. sc514) can inhibit both the degradation of I κ B α and the phosphorylation/acetylation of p65, thus counteracting the potentiating effects of HDACi on NF- κ B activity.

	SHORT-TERM EFFECTS	LONG-TERM EFFECTS
Transcription factors		
NF- κ B	Increased nuclear localisation, DNA binding, and transcriptional activity	Decreased DNA binding
c-Jun	Decreased expression and nuclear levels	Decreased expression and nuclear levels
IκBα gene		
	Increased expression	No effect
Pro-inflammatory genes		
COX-2	Decreased expression	Decreased expression
IL-8	Decreased expression	Decreased expression
IL-6	Decreased expression	Decreased expression
RANTES	Decreased expression	Decreased expression

Table 1. Summary of the short-term and long-term effects of HDAC inhibitors on pro-inflammatory transcription factors and genes in IL-1 β -stimulated myometrial cells.










Fig.2




Fig.3






Fig. 4






Fig.5











Figure 8

A. Acetylation in IL-1 β -induced NF- κ B signalling



TSA/SAHA

B. Primary effects of HDAC inhibition

